Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Meiji Seika Aims at \10 Bil. Sales with Generics
January 21, 2008
- NEW PRODUCTS／Dinagest Tablet for Endometriosis: Mochida
January 21, 2008
- Taisho Licenses TS-032 to Pfizer
January 21, 2008
- Tacere to Codevelop RNAi Hepatitis C Drug with Pfizer
January 21, 2008
- Mochida Licenses Analgesic to Wyeth
January 21, 2008
- Toyama Starts PII Study for T-705
January 21, 2008
- Novartis to Close Its Tsukuba Research Institute
January 21, 2008
- R&D NEWS IN BRIEF
January 21, 2008
- How Can I Grow My Brand without Growing My Budget?
January 21, 2008
- SURVEY／Patients with Serious Diseases More Likely to Quit Smoking
January 21, 2008
- Excessive Rebates May Violate Antimonopoly Law: Ihoken
January 21, 2008
- Teijin Pharma Enters US Market for Home Healthcare Equipment
January 21, 2008
- All Concerned Parties Should Cooperate to Improve Business Practices: Mr Matsutani
January 21, 2008
- Health Net and Med-Solution to Form Alliance for Clinical Imaging Studies
January 21, 2008
- PMDA to Expand Review System for Generics, OTC Drugs: Chief Executive Miyajima
January 21, 2008
- MEDICAL DEVICE NEWS IN BRIEF
January 21, 2008
- Korosho to Expand System to Determine Market Trend for Generics
January 21, 2008
- Reimbursement Prices for 5 Chemotherapy Regimens under DPC System to Be Reconsidered
January 21, 2008
- Nichi-Iko Improves Distribution, Production Systems to Ensure Overnight Deliveries
January 21, 2008
- Int'l Cooperation Needed to Eliminate Counterfeit Drugs: Prof. Kimura
January 21, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…